Formulation Development
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
Aravive, Inc. recently announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three…
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial
Mustang Bio, Inc. recently announced that the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration…
Diasome Announces Positive Results from Phase 2 OPTI-1 Study
Diasome Pharmaceuticals, Inc. recently announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with…
Annovis Issued Patent for Method of Treating Parkinson’s Disease & Other Lewy Body Diseases
Annovis Bio Inc. was recently issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia, and other…
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
Alkahest Announces Initiation of Phase 2b Clinical Trial
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
Cocrystal Pharma's Structure-Based Technology Demonstrated Broad Utility
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics using its proprietary structure-based drug discovery platform technology to create first-and…
Oculis Announces Positive OCS-01 Phase 2 Data
Oculis S.A. recently reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment…
Zumutor Biologics & Catalent Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Catalent recently announced it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor…
BeyondSpring’s Plinabulin Stimulates Both the Adaptive & Innate Immune System
BeyondSpring Inc. recently announced that new clinical data on the company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.…
Biologics Patent Expiry Trend Expected to Have Positive Impact
Expectations for biosimilars are high in 2020, and the drug class will finally begin to make its mark in the US, says GlobalData, a leading…
Synteract Expands Into Asia Pacific & South Africa Through Acquisition of Specialty Biometrics CRO
Synteract recently acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint…
CURE Pharmaceutical Signs Exclusive Licensing Agreement With ReLeaf Europe
CURE Pharmaceutical recently announced it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.…
AskBio Announces First Patient Dosed in Phase 1 Trial
Asklepios BioPharmaceutical (AskBio) and its NanoCor Therapeutics subsidiary recently announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101.…
Cellectricon & StressMarq Biosciences Collaborate to Develop Next-Generation Reagents & Assays
Cellectricon recently announced a collaboration with StressMarq Biosciences. As a supplier of life science reagents such as primary antibodies, antibody conjugates, proteins, immunoassay kits and…
PharmaCyte Biotech Will Have All the Protection It Needs Upon Marketing Approval
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Catalent to Acquire Leading Cell Therapy Company MaSTherCell Global
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..
Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement
Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….
BioPharmX & Timber Pharmaceuticals Announce Merger Agreement
BioPharmX Corporation and Timber Pharmaceuticals LLC recently announced they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of…..
